Article
The first generic version of Accutane (isotretinoin), approved Nov. 11 by the FDA, reached market in late November at a price approximately 5.5 percent lower than the brand name.
Review Compares Psoriasis Therapies in Asian Populations
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
Subgroup Analysis Reveals Equal Benefit of Brodalumab in Obese vs Non-Obese Patients With Psoriasis
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Patients Treated for Acne Exhibit Higher Sebum, Hydration, and TEWL Levels than General Population
Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases